Evidence map›Paper›PMID 27920508›Full record

Trial reportClinical interventions in aging2016

Impact of whole body electromyostimulation on cardiometabolic risk factors in older women with sarcopenic obesity: the randomized controlled FORMOsA-sarcopenic obesity study.

Katharina Wittmann, Cornel Sieber, Simon von Stengel, Matthias Kohl, Ellen Freiberger, Franz Jakob, Michael Lell, Klaus Engelke, Wolfgang Kemmler

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical interventions in aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Sarcopenic obesity: emerging mechanisms and therapeutic potential.Metabolism: clinical and experimental · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katharina WittmannInstitute of Medical Physics, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg.
Cornel SieberInstitute for Biomedicine of Aging, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen.
Simon von StengelInstitute of Medical Physics, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg.
Matthias KohlFaculty of Medical and Life Sciences, University of Furtwangen.
Ellen FreibergerInstitute for Biomedicine of Aging, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen.
Franz JakobMusculoskeletal Research Center, University of Würzburg, Würzburg.
Michael LellDepartment of Radiology and Nuclear Medicine, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Nürnberg, Germany.
Klaus EngelkeInstitute of Medical Physics, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg.
Wolfgang KemmlerInstitute of Medical Physics, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcopenic obesity (SO) is characterized by a combination of low muscle and high fat mass with an additive negative effect of both conditions on cardiometabolic risk. The aim of the study was to determine the effect of whole-body electromyostimulation (WB-EMS) on the metabolic syndrome (MetS) in community-dwelling women aged ≥70 years with SO.

methodsThe study was conducted in an ambulatory university setting. Seventy-five community-dwelling women aged ≥70 years with SO living in Northern Bavaria, Germany, were randomly allocated to either 6 months of WB-EMS application with (WB-EMS&P) or without (WB-EMS) dietary supplementation (150 kcal/day, 56% protein) or a non-training control group (CG). WB-EMS included one session of 20 min (85 Hz, 350 μs, 4 s of strain-4 s of rest) per week with moderate-to-high intensity. The primary study endpoint was the MetS Z-score with the components waist circumference (WC), mean arterial pressure (MAP), triglycerides, fasting plasma glucose, and high-density lipoprotein cholesterol (HDL-C); secondary study endpoints were changes in these determining variables.

resultsMetS Z-score decreased in both groups; however, changes compared with the CG were significant (

conclusionThe study clearly confirms the favorable effect of WB-EMS application on the MetS in community-dwelling women aged ≥70 years with SO. However, protein-enriched supplements did not increase effects of WB-EMS alone. In summary, we considered this novel technology an effective and safe method to prevent cardiometabolic risk factors and diseases in older women unable or unwilling to exercise conventionally.

Indexed as

AgedAged, 80 and overArterial PressureCholesterol, HDLDietary SupplementsDouble-Blind MethodElectric Stimulation TherapyFemaleGermanyHumansMetabolic SyndromeObesityRisk FactorsSarcopeniaTreatment OutcomeTriglyceridesCholesterol, HDLTriglyceridescardiovascularcommunity-dwellingmetabolic riskmetabolic syndromeobesityolder peoplesarcopeniawhole-body electromyostimulation

Identifiers

PMID27920508
PMCPMC5123721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.